FLORENCY, Ky., Sept. 29, 2011 (GLOBE NEWSWIRE) -- Immudyne, Inc. (Pink Sheets:IMMD) a leading industry provider of all-natural products for immune system support from yeast beta-glucan, is pleased to announce the retirement of 1,136,842 shares of the Company's common stock purchased in a recent private transaction. Mark McLaughlin, CEO of Immudyne, stated, "The retiring of these shares is part of ongoing efforts to enhance the value of our long-term shareholders' ownership in Immudyne. With only 24.5 million shares currently outstanding, and virtually no company debt, our capital structure accommodates future growth both organically and through strategic opportunities."
Immudyne is planning retiring additional shares in the very near future, which would include open market purchases.
Additional recent company milestones include:
* PFK LLP, New York, completed audited Financials for years 2009 and 2010 (clean opinion)
* new corporate website: www.immudyne.com
* re-purchased and retired 3 million options
* upgraded OTC markets (www.otcmarkets.com) status to Fully Current
* hired industry veteran Jim Roufs as Director of Product Development
About Immudyne
Immudyne manufactures, distributes and sells patented and proprietary all-natural yeast beta glucan products for immune system support.
Immudyne shares trade under the ticker symbol IMMD and the Company can be found on the web at www.globenewswire.com/newsroom/ctr%3Fd=216160%26l=7%26a=www.immudyne.com%26u=http%253A%252F%252Fwww.immudyne.com" target="_blank">www.immudyne.com (currently being transformed.) Cautionary language regarding Forward-Looking Statements Safe Harbor Act Disclaimer: Forward-looking statements in this release are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Certain statements in this press release may contain words such as "anticipates,""believes," "could," "estimates," "expects," "intends," "may," "projects," "plans," "targets" and other similar language and are considered forward-looking statements. These statements are based on management's current expectations, estimates, and forecasts. These forward-looking statements are subject to important assumptions, risks and uncertainties, which are difficult to predict and therefore the actual results may be materially different from those discussed.